Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | NPC1 | O15118 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219755 | 0.88 | RAB9A (0.64) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL335645 | 0.86 | NPC1 (0.64) | RAB9ANPC1MAPTSMN1; SMN2PPARG | |
| SCHEMBL10219811 | 0.85 | MAPT (0.58) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL10219864 | 0.83 | PPARG (0.48) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL10219800 | 0.79 | NPC1 (0.50) | RAB9ANPC1MAPTSMN1; SMN2PPARG | |
| SCHEMBL1094846 | 0.78 | NPC1 (0.75) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL3468742 | 0.77 | RAB9A (0.70) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL1094816 | 0.77 | NPC1 (0.73) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL1095922 | 0.76 | RAB9A (0.64) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL1095926 | 0.76 | RAB9A (0.64) | RAB9ANPC1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | RAB9A 1784/4885NPC1 1742/4885MAPT 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.